Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
FTC/TDF tablet reduces HIV infection among high-risk individuals: iPrEx study

FTC/TDF tablet reduces HIV infection among high-risk individuals: iPrEx study

GCM supports iPrEx Study to prevent HIV infection among MSM

GCM supports iPrEx Study to prevent HIV infection among MSM

Important queries about PrEP, iPrEx trial for HIV infection

Important queries about PrEP, iPrEx trial for HIV infection

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

HIV treatment drugs also help prevent HIV infection in high-risk men: Study

iPrEx study: PrEP reduces HIV infection risk among gay, bisexual men

iPrEx study: PrEP reduces HIV infection risk among gay, bisexual men

Daily oral antiretroviral reduces HIV infection risk in MSM by 44%, study finds

Daily oral antiretroviral reduces HIV infection risk in MSM by 44%, study finds

CONRAD congratulates Global iPrEx study team for HIV prevention trial

CONRAD congratulates Global iPrEx study team for HIV prevention trial

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency

Tibotec submits MAA for investigational HIV drug TMC278 to European Medicines Agency

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Gilead Sciences seeks MAA in Europe for fixed-dose combination of Truvada and TMC278 for HIV-1 infection

Merck and Bill & Melinda Gates Foundation commit additional $60M to support Botswana's ACHAP

Merck and Bill & Melinda Gates Foundation commit additional $60M to support Botswana's ACHAP

Bristol-Myers Squibb, ACTF announce enhanced agreement to support ADAPs

Bristol-Myers Squibb, ACTF announce enhanced agreement to support ADAPs

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

Tibotec submits NDA for TMC278 anti-HIV compound to FDA

Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint

Boehringer Ingelheim's VERxVE study of nevirapine meets primary endpoint

New HIV drug on the block

New HIV drug on the block

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Study marks significant milestone for microbicide research field, HIV prevention

Study marks significant milestone for microbicide research field, HIV prevention